Herceptin biosimilar development assessed in new MP Advisors research study

October 16, 2012 6:43 AM

New research study “Risk – Reward of Developing a Herceptin Biosimilar – A Thorough Assessment” worked out by MP Advisors has been recently published by Market Publishers Ltd. 

The report states that Herceptin sales are particularly critical to Roche as it accounts for about 15% of its cumulative pharmaceuticals sales.

With Herceptin exclusivity expiring in major geographies, a host of experienced as well as new entrant biosimilar players start eying for a lucrative opportunity to grab a share of this potential USD 6 billion pie. Herceptin sales are particularly critical to Roche as it accounts for about 15% of its cumulative pharmaceuticals sales. However, with all these great opportunities surrounding biosimilar players, there exist certain risks and barriers to be aware of.

New research study “Risk – Reward of Developing a Herceptin Biosimilar – A Thorough Assessment” worked out by MP Advisors has been recently published by Market Publishers Ltd.

Report Details: Risk – Reward of Developing a Herceptin Biosimilar – A Thorough Assessment
Published: October, 2012
Pages: 70
Price: US$ 2,000.00
Link: www.marketpublishers.com

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!